Risk Stratification for Smoldering Myeloma | Irene Ghobrial, MD | IMS 2024

(3:47)

Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023

(1:31)

Myeloma Crowd Radio: Dr. Irene Ghobrial, MD, Dana Farber Cancer Institute

(30:45)

Advances being made in high-risk smoldering myeloma: ongoing trials \u0026 promising agents

(1:33)

Dr. Irene Ghobrial | CPOP | Dana-Farber Cancer Institute

(4:31)

mPatient Myeloma Radio: Dr. Irene Ghobrial MD, PhD, Dana Farber Cancer Institute

(58:25)

Defining precursor conditions in multiple myeloma \u0026 strategies to better predict risk of progression

(2:31)

Early Detection and Interception in Multiple Myeloma: Irene Ghobrial, MD

(21:18)

Multiple Myeloma – Is It Now a Curable Disease?

(16:56)

Multiple Myeloma Precursor Conditions | Overview | Therapeutic Intervention

(49:36)

How Is MGUS Monitored?

(5:34)

Andy, multiple myeloma survivor

(7:24)

The Truth About MGUS

(4:16)

2/10/17: Multiple Myeloma: The Good, the Bad and the Ugly

(52:22)

The PROMISE of Early Detection and Interception in Myeloma

(20:33)

Myeloma Patients Have New Hope Thanks to New Treatments

(4:3)

Approaches to risk stratification in high risk myeloma

(4:16)

Treating rare blood cancers: Dr. Irene Ghobrial | Dana-Farber Cancer Institute

(1:28)

Should we treat smoldering multiple myeloma?

(1:22)

ASH Meeting on Hematologic Malignancies: Irene Ghobrial, MD

(1:14)

HealthTree Podcast for Myeloma: Irene Ghobrial, MD, Dana Farber Cancer Institute

(1:3:35)

Early identification of myeloma to prevent disease progression

(59)

Factors to consider when choosing between ‘watch and wait’ versus early intervention in SMM

(2:45)

Understanding MGUS and SMM Progression - Irene Ghobrial, MD | MCRT Webcast September 26 (2/3)

(12:38)

The challenges of studying the progression and biology of myeloma

(1:11)

Smoldering myeloma: state of the art

(3:37)

ASH 2019: High-Risk Smoldering Myeloma Treatment Research | Dr. Irene Ghobrial

(2:1econd)

Irene Ghobrial, M.D., Dana-Farber Cancer Institute, Myeloma

(2:5)

Prof. Irene Ghobrial

(1:29)

Genomic profiling of smoldering myeloma to improve risk stratification models

(1:33)